Blocking tumor escape in hematologic malignancies

The anti-PD-1 strategy

Locke Johnson Bryan, Leo I. Gordon

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

Immunotherapy remains an important tool for treatment of hematologic malignancies. The Programmed Death-1 (PD-1) immune checkpoint pathway has emerged as a mechanism of tumor evasion from the anti-tumor immune response. The recent development of anti-PD-1 monoclonal antibodies has offered a targeted approach to cancer therapy. Several agents are in various stages of development and have shown clinical responses across a broad spectrum of both solid and hematologic malignancies. The use of anti-PD-1 therapy in hematologic malignancies is limited but has demonstrated clinical responses in relapsed/refractory disease following multiple lines of therapy. PD-1 blockade may reduce relapse rates for patients who fail to obtain a complete remission prior to autologous hematopoietic cell transplant. The role of the PD-1 pathway for tumor escape is reviewed. We explore the use of anti-PD-1 therapy in hematologic malignancies. The proposed mechanism of PD-1 blockade as a modulator of the innate and acquired immune response is considered. Finally, the challenges of anti-PD-1 therapy and the future direction of investigation in this area are reviewed.

Original languageEnglish (US)
Pages (from-to)25-32
Number of pages8
JournalBlood Reviews
Volume29
Issue number1
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Tumor Escape
Hematologic Neoplasms
Therapeutics
Innate Immunity
Immunotherapy
Neoplasms
Monoclonal Antibodies
Transplants
Recurrence

Keywords

  • Follicular lymphoma
  • Hematologic malignancies
  • Hodgkin lymphoma
  • Monoclonal antibody
  • Non-Hodgkin lymphoma (NHL)
  • Plasma cell myeloma (PCM)
  • Programmed Death-1 (PD-1)

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Medicine(all)

Cite this

Blocking tumor escape in hematologic malignancies : The anti-PD-1 strategy. / Bryan, Locke Johnson; Gordon, Leo I.

In: Blood Reviews, Vol. 29, No. 1, 01.01.2015, p. 25-32.

Research output: Contribution to journalReview article

@article{ebc9fc549ae34faf832685fefff9180d,
title = "Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy",
abstract = "Immunotherapy remains an important tool for treatment of hematologic malignancies. The Programmed Death-1 (PD-1) immune checkpoint pathway has emerged as a mechanism of tumor evasion from the anti-tumor immune response. The recent development of anti-PD-1 monoclonal antibodies has offered a targeted approach to cancer therapy. Several agents are in various stages of development and have shown clinical responses across a broad spectrum of both solid and hematologic malignancies. The use of anti-PD-1 therapy in hematologic malignancies is limited but has demonstrated clinical responses in relapsed/refractory disease following multiple lines of therapy. PD-1 blockade may reduce relapse rates for patients who fail to obtain a complete remission prior to autologous hematopoietic cell transplant. The role of the PD-1 pathway for tumor escape is reviewed. We explore the use of anti-PD-1 therapy in hematologic malignancies. The proposed mechanism of PD-1 blockade as a modulator of the innate and acquired immune response is considered. Finally, the challenges of anti-PD-1 therapy and the future direction of investigation in this area are reviewed.",
keywords = "Follicular lymphoma, Hematologic malignancies, Hodgkin lymphoma, Monoclonal antibody, Non-Hodgkin lymphoma (NHL), Plasma cell myeloma (PCM), Programmed Death-1 (PD-1)",
author = "Bryan, {Locke Johnson} and Gordon, {Leo I.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.blre.2014.09.004",
language = "English (US)",
volume = "29",
pages = "25--32",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - Blocking tumor escape in hematologic malignancies

T2 - The anti-PD-1 strategy

AU - Bryan, Locke Johnson

AU - Gordon, Leo I.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Immunotherapy remains an important tool for treatment of hematologic malignancies. The Programmed Death-1 (PD-1) immune checkpoint pathway has emerged as a mechanism of tumor evasion from the anti-tumor immune response. The recent development of anti-PD-1 monoclonal antibodies has offered a targeted approach to cancer therapy. Several agents are in various stages of development and have shown clinical responses across a broad spectrum of both solid and hematologic malignancies. The use of anti-PD-1 therapy in hematologic malignancies is limited but has demonstrated clinical responses in relapsed/refractory disease following multiple lines of therapy. PD-1 blockade may reduce relapse rates for patients who fail to obtain a complete remission prior to autologous hematopoietic cell transplant. The role of the PD-1 pathway for tumor escape is reviewed. We explore the use of anti-PD-1 therapy in hematologic malignancies. The proposed mechanism of PD-1 blockade as a modulator of the innate and acquired immune response is considered. Finally, the challenges of anti-PD-1 therapy and the future direction of investigation in this area are reviewed.

AB - Immunotherapy remains an important tool for treatment of hematologic malignancies. The Programmed Death-1 (PD-1) immune checkpoint pathway has emerged as a mechanism of tumor evasion from the anti-tumor immune response. The recent development of anti-PD-1 monoclonal antibodies has offered a targeted approach to cancer therapy. Several agents are in various stages of development and have shown clinical responses across a broad spectrum of both solid and hematologic malignancies. The use of anti-PD-1 therapy in hematologic malignancies is limited but has demonstrated clinical responses in relapsed/refractory disease following multiple lines of therapy. PD-1 blockade may reduce relapse rates for patients who fail to obtain a complete remission prior to autologous hematopoietic cell transplant. The role of the PD-1 pathway for tumor escape is reviewed. We explore the use of anti-PD-1 therapy in hematologic malignancies. The proposed mechanism of PD-1 blockade as a modulator of the innate and acquired immune response is considered. Finally, the challenges of anti-PD-1 therapy and the future direction of investigation in this area are reviewed.

KW - Follicular lymphoma

KW - Hematologic malignancies

KW - Hodgkin lymphoma

KW - Monoclonal antibody

KW - Non-Hodgkin lymphoma (NHL)

KW - Plasma cell myeloma (PCM)

KW - Programmed Death-1 (PD-1)

UR - http://www.scopus.com/inward/record.url?scp=84921793999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921793999&partnerID=8YFLogxK

U2 - 10.1016/j.blre.2014.09.004

DO - 10.1016/j.blre.2014.09.004

M3 - Review article

VL - 29

SP - 25

EP - 32

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

IS - 1

ER -